ArticleAbdominal radiology (New York)2026
A modified Rim APHE criterion to improve LI-RADS diagnostic performance for primary liver malignancies.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo refine the diagnostic criteria for rim arterial phase hyperenhancement (Rim APHE) and to evaluate the impact of this modification on the diagnostic performance for primary liver malignancies. MATERIALS AND
methodsThis multicenter, retrospective study included patients with pathologically confirmed primary liver malignancies who underwent preoperative magnetic resonance imaging (MRI) before June 2021. Thirteen different measurement methods for Rim APHE were evaluated to determine the optimal criterion based on diagnostic performance. Two radiologists independently reviewed all observations, assigned Liver Imaging Reporting and Data System (LI-RADS) categories according to version 2018. The diagnostic performance of LI-RADS using original versus modified Rim APHE criteria was compared.
resultsThe study enrolled 272 patients, including 204 with Hepatocellular carcinoma (HCC) (170 men and 34 women; mean age, 57 years ±10) and 68 with non-HCC malignancies (53 men and 15 women; mean age, 56 years ±10). The optimal criterion for Rim APHE was the total thickness of the thickest part of peripheral hyperenhancement to tumor diameter (area under the receiver operating characteristic (ROC) curve [AUC] = 0.852; P < .001). With implementation of the modified Rim APHE criterion, the LR-5 criteria showed significantly superior AUC (0.770 vs. 0.752, p = .007), sensitivity (76.0% vs. 72.5%, p = .016) and accuracy (76.5% vs. 73.9%, p = .016); the LR-M criteria showed higher AUC (0.831 vs. 0.811, p = .004), specificity (92.7% vs. 88.7%, p = .008) and accuracy (87.9% vs. 84.9%, p = .008).
conclusionThe optimal criterion for Rim APHE can improve the diagnostic performance for both HCC and non-HCC malignancies.
Indexed as
Identifiers
42138744What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.